AlphAIAlphAI — Financial news for AI agents
SEC EDGARSEP 31 min read$APGE

Henderson Jane sold (to issuer) 158,371 shares of APGE

Henderson Jane (Chief Financial Officer) sold (to issuer) 158,371 shares of Apogee Therapeutics, Inc. (APGE) on 2026-09-03.

Original reporting
SEC EDGAR · Henderson Jane
Published Sep 3, 2026, 4:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 4, 2026, 7:09 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$APGE
Neutral
medium confidence
Mentioned
$APGE
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$APGENeutralLow
01

Why it matters

The filing provides the first public disclosure of the CFO's complete exit from APGE shares.

02

Market read

A primary insider sale by a senior executive, modest in size, may cause slight short‑term price pressure.

03

What to watch

No price disclosed; CFO may have pre‑arranged tax or personal reasons.

Relevance 4/10Novelty 4/10Timing: 2026-09-03 (same‑day filing)

Background

Form 4 filings disclose insider transactions; CFOs selling large positions can attract attention.

Company-level read

Ticker impact

$APGENeutralMedium confidence
Context

CFO Henderson Jane sold her entire 158,371 shares in a Form 4 filing, reducing insider ownership to zero.

Expected impact

Possible slight downside pressure in the short term.

Evidence & confidence

Insider sales by senior executives can be viewed negatively, but the transaction size is modest and price was not disclosed.

Market effects

Sector

Minimal impact on the biotech sector; typical insider sale.

Regional

None

Global

None

Counterpoint

What could challenge this read

The sale could be a routine liquidity event unrelated to company outlook.

Key entities

  • Company
    Apogee Therapeutics, Inc.

    Biotech firm listed on NASDAQ under ticker APGE.

  • Person
    Henderson Jane

    Chief Financial Officer of Apogee Therapeutics.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

APGE insider trading history →

Related articles

SEP 9
$ABBVHighAI 9/10

Is AbbVie (ABBV)’s $10.9 Billion Apogee Therapeutics (APGE) Deal the Next Catalyst for Growth?

AbbVie (ABBV) completed its $10.9B acquisition of Apogee Therapeutics (APGE) at $135.11 per share. AbbVie also reported positive Phase 3 trial results for etentamig. Q2 2026 revenue for AbbVie rose 10.2% to $16.99B, with adjusted EPS up 22.9% to $3.65. Apogee reported a net loss of $85.9M in Q2 2026. Hedge funds increased stakes in both companies ahead of the deal.

insidermonkey.com3 min
SEP 3
$ABBVHighAI 9/10

AbbVie Completes $10.9 Bln Acquisition Of Apogee Therapeutics

AbbVie (ABBV) completed its $10.9 billion acquisition of Apogee Therapeutics (APGE), paying $135.11 per share. The deal strengthens AbbVie's immunology pipeline, including Apogee's lead asset, zumilokibart, for atopic dermatitis. AbbVie expects the acquisition to be dilutive to earnings until 2032. AbbVie reaffirmed its 2026 EPS guidance of $13.87-$14.07, including a $0.14 per-share dilutive impact. ABBV closed at $261.72, up 0.67%.

rttnews.com2 min
SEP 2
$MMEDMed

Biotech Stocks At 52-Week Highs - MMED +10%, PLSE, SOLV, RPRX, APGE

Several biotech stocks hit 52-week highs on September 1, 2026. MiniMed Group (MMED) rose 10% to $22.74 with 16.6% sales growth. Pulse Biosciences (PLSE) gained 3% to $54.39. Solventum (SOLV) reached $94.16 with 2.2% revenue growth. Royalty Pharma (RPRX) climbed to $62.58 with 14% royalty receipts growth. Apogee Therapeutics (APGE) hit $135.09 and will be acquired by AbbVie for $10.9B.

rttnews.com2 min